A Smart Loan Deal for a Biotech Company

A small French eye-care company just lined up a financial safety net worth €6 million. It’s not a loan you’d get from a bank—it’s a special kind of credit from a long-time shareholder. The catch? If the company ever uses the full amount, the lender could end up owning nearly 15% of the business. That’s a big slice of the pie. The loan sits on standby for three years. The company doesn’t have to take a single euro if it doesn’t need to. If it ever taps the credit line, it can pay back in either cash or new shares. Choosing shares keeps the cash in the business but waters down existing owners’ control.Behind the scenes, this is all about timing. The company already expects enough cash from its main drug, NCX 470, to last past 2027. The drug is in late-stage testing and could hit the U. S. market this summer. If regulators approve it, steady sales could keep the lights on for years. Still, extra money never hurts. The extra cash could fund new experiments, buy smaller firms, or simply give leaders more room to negotiate. The lender—Vester Finance—knows the company well and agreed to a 7% yearly interest rate that only kicks in if the company ever repays in cash. The biggest worry? When the company issues new shares, their value gets split even more. A shareholder with 1% of the pie before the deal could shrink to less than 0. 7% afterward. The company promises this won’t shake up how it’s run.